304 related articles for article (PubMed ID: 26900475)
1. Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases.
Das Gupta K; Shakespear MR; Iyer A; Fairlie DP; Sweet MJ
Clin Transl Immunology; 2016 Jan; 5(1):e62. PubMed ID: 26900475
[TBL] [Abstract][Full Text] [Related]
2. Role of Histone Deacetylases in Monocyte Function in Health and Chronic Inflammatory Diseases.
Tordera RM; Cortés-Erice M
Rev Physiol Biochem Pharmacol; 2021; 180():1-47. PubMed ID: 33974124
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
Cantley MD; Zannettino ACW; Bartold PM; Fairlie DP; Haynes DR
Bone; 2017 Feb; 95():162-174. PubMed ID: 27913271
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
[TBL] [Abstract][Full Text] [Related]
6. Functional Analysis of HDACs in Tumorigenesis.
Hadley M; Noonepalle S; Banik D; Villagra A
Methods Mol Biol; 2019; 1983():279-307. PubMed ID: 31087305
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases as regulators of inflammation and immunity.
Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
Turtoi A; Peixoto P; Castronovo V; Bellahcène A
Crit Rev Oncog; 2015; 20(1-2):119-37. PubMed ID: 25746107
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
Van den Bossche J; Neele AE; Hoeksema MA; de Heij F; Boshuizen MC; van der Velden S; de Boer VC; Reedquist KA; de Winther MP
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):396-402. PubMed ID: 25446073
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW; Akimova T; Beier UH; Liu Y; Wang L
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i46-54. PubMed ID: 22460138
[TBL] [Abstract][Full Text] [Related]
12. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW
Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
[TBL] [Abstract][Full Text] [Related]
13. Activity and expression of histone acetylases and deacetylases in inflammatory phenotypes of asthma.
Gunawardhana LP; Gibson PG; Simpson JL; Powell H; Baines KJ
Clin Exp Allergy; 2014 Jan; 44(1):47-57. PubMed ID: 24355018
[TBL] [Abstract][Full Text] [Related]
14. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
15. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylase as a new mechanism of teratogenesis.
Menegola E; Di Renzo F; Broccia ML; Giavini E
Birth Defects Res C Embryo Today; 2006 Dec; 78(4):345-53. PubMed ID: 17315247
[TBL] [Abstract][Full Text] [Related]
17. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
Felice C; Lewis A; Armuzzi A; Lindsay JO; Silver A
Aliment Pharmacol Ther; 2015 Jan; 41(1):26-38. PubMed ID: 25367825
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Grabiec AM; Krausz S; de Jager W; Burakowski T; Groot D; Sanders ME; Prakken BJ; Maslinski W; Eldering E; Tak PP; Reedquist KA
J Immunol; 2010 Mar; 184(5):2718-28. PubMed ID: 20100935
[TBL] [Abstract][Full Text] [Related]
19. Modulation of immune responses by histone deacetylase inhibitors.
Schotterl S; Brennenstuhl H; Naumann U
Crit Rev Oncog; 2015; 20(1-2):139-54. PubMed ID: 25746108
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
